Clinical Trials
12 trialsNCT05365893 2026-05-22
PHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04106856 2026-05-12
SHAPER
University of Utah
Phase 1 Active not recruiting
NCT05077800 2026-04-13
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07160361 2025-09-16
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
Second Affiliated Hospital of Xi'an Jiaotong University
Phase 4 Not yet recruiting
NCT05861336 2024-12-27
OVERPASS
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT06539806 2024-08-06
Clinical Study Evaluating the Effect of Losartan
Tanta University
Phase NA Recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT05871333 2023-07-19
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
Ain Shams University
Phase 2 Unknown
NCT01821729 2020-09-25
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT01276613 2019-05-02
Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated